Effect of genetic variants GSTA1 and CYP39A1 and age on busulfan clearance in pediatric patients undergoing hematopoietic stem cell transplantation

Pharmacogenomics

Volumn 14, Issue 14, 2013, Pages 1683-1690

  Ten Brink, Marloes H ^a   Van Bavel, Tom ^a   Swen, Jesse J ^a   Straaten, Tahar Van Der ^a   Bredius, Robbert Gm ^a   Lankester, Arjan C ^a   Zwaveling, Juliëtte ^a   Guchelaar, Henk Jan ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Busulfan; Hematopoietic stem cell transplantation; Pediatric patients; Pharmacogenetics; Pharmacokinetics

Indexed keywords

ALEMTUZUMAB; BUSULFAN; CARNITINE TRANSPORTER 1; CLOFARABINE; CLONAZEPAM; CYCLOPHOSPHAMIDE; CYTOCHROME P450 2C19; ETOPOSIDE; FLUDARABINE; GLUTATHIONE TRANSFERASE A1; MELPHALAN; MULTIDRUG RESISTANCE PROTEIN 3; THIOTEPA; THYMOCYTE ANTIBODY; CYP39A1 PROTEIN, HUMAN; GLUTATHIONE S-TRANSFERASE ALPHA; GLUTATHIONE TRANSFERASE; ISOENZYME; STEROID MONOOXYGENASE;

ABCB4 GENE; ADULT; AGE; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; AREA UNDER THE CURVE; ARTICLE; BETA THALASSEMIA; CHILD; CYP2C19 GENE; CYP39A1 GENE; DRUG BLOOD LEVEL; DRUG CLEARANCE; FEMALE; GENE; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC MARKER; GENETIC VARIABILITY; GENOTYPE; GSTA1 GENE; HAPLOTYPE; HEMATOLOGIC DISEASE; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNE DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; PHARMACOGENETICS; RETROSPECTIVE STUDY; SEIZURE; SINGLE NUCLEOTIDE POLYMORPHISM; SLC22A4 GENE; SLC7A8 GENE; ADOLESCENT; GENETICS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; PRESCHOOL CHILD;

ADOLESCENT; BUSULFAN; CHILD; CHILD, PRESCHOOL; FEMALE; GENETIC ASSOCIATION STUDIES; GLUTATHIONE TRANSFERASE; HAPLOTYPES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; ISOENZYMES; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; STEROID HYDROXYLASES; TRANSPLANTATION CONDITIONING;

EID: 84897089915     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.13.159     Document Type: Article

References (28)

1. Grochow LB, Jones RJ, Brundrett RB et al. Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation. Cancer Chemother. Pharmacol. 25(1), 55-61 (1989).
2. Ljungman P, Hassan M, Bekassy AN, Ringden O, Oberg G. High busulfan concentrations are associated with increased transplant-related mortality in allogeneic bone marrow transplant patients. Bone Marrow Transplant. 20(11), 909-913 (1997).
3. McCune JS, Gibbs JP, Slattery JT. Plasma concentration monitoring of busulfan: does it improve clinical outcome? Clin. Pharmacokinet. 39(2), 155-165 (2000).
4. Slattery JT, Clift RA, Buckner CD et al. Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation. Blood 89(8), 3055-3060 (1997).
5. Lee JW, Kang HJ, Lee SH et al. Highly variable pharmacokinetics of once-daily intravenous busulfan when combined with fludarabine in pediatric patients: Phase I clinical study for determination of optimal once-daily busulfan dose using pharmacokinetic modeling. Biol. Blood Marrow Transplant. 18(6), 944-950 (2012).
6. Paci A, Vassal G, Moshous D et al. Pharmacokinetic behavior and appraisal of intravenous busulfan dosing in infants and older children. Ther. Drug Monit. 34(2), 198-208 (2012).
7. Malär R, Sjöö F, Rentsch K, Hassan M, Güngör T. Therapeutic drug monitoring is essential for intravenous busulfan therapy in pediatric hematopoietic stem cell recipients. Pediatr. Transplant. 15(6), 580-588 (2011).
8. Zwaveling J, den Hartigh J, Lankester AC, Guchelaar HJ, Egeler RM, Bredius RG. Once-daily intravenous busulfan in children prior to stem cell transplantation: study of pharmacokinetics and early clinical outcomes. Anticancer Drugs 17(9), 1099-1105 (2006).
9. McCune JS, Holmberg LA. Busulfan in hematopoietic stem cell transplant setting. Expert Opin. Drug Metab. Toxicol. 5(8), 957-969 (2009).
10. Kim SD, Lee JH, Hur EH et al. Influence of GST gene polymorphisms on the clearance of intravenous busulfan in adult patients undergoing hematopoietic cell transplantation. Biol. Blood Marrow Transplant. 17(8), 1222-1230 (2011).
11. ten Brink MH, Wessels JA, den Hartigh J et al. Effect of genetic polymorphisms in genes encoding GST isoenzymes on BU pharmacokinetics in adult patients undergoing hematopoietic SCT. Bone Marrow Transplant. 47(2), 190-195 (2012).
12. Johnson L, Orchard PJ, Baker KS et al. Glutathione S-transferase A1 genetic variants reduce busulfan clearance in children undergoing hematopoietic cell transplantation. J. Clin. Pharmacol. 48(9), 1052-1062 (2008).
13. Zwaveling J, Press RR, Bredius RG et al. Glutathione S-transferase polymorphisms are not associated with population pharmacokinetic parameters of busulfan in pediatric patients. Ther. Drug Monit. 30(4), 504-510 (2008).
14. Ansari M, Lauzon-Joset JF, Vachon MF et al. Influence of GST gene polymorphisms on busulfan pharmacokinetics in children. Bone Marrow Transplant. 45(2), 261-267 (2010).
15. Gaziev J, Nguyen L, Puozzo C et al. Novel pharmacokinetic behavior of intravenous busulfan in children with thalassemia undergoing hematopoietic stem cell transplantation: a prospective evaluation of pharmacokinetic and pharmacodynamic profile with therapeutic drug monitoring. Blood 115(22), 4597-4604 (2010).
16. Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE. Developmental pharmacology -drug disposition, action, and therapy in infants and children. N. Engl. J. Med. 349(12), 1157-1167 (2003).
17. ten Brink MH, Swen J, Wessels JA et al. Exploratory analysis of 1,936 SNPs in ADME genes for association with busulfan clearance in adult hematopoietic stem cell recipients. Pharmacogenet. Genomics (2013) (In Press).
18. Cremers S, Schoemaker R, Bredius R et al. Pharmacokinetics of intravenous busulfan in children prior to stem cell transplantation. Br. J. Clin. Pharmacol. 53(4), 386-389 (2002).
19. Proost JH, Meijer DK. MW/Pharm, an integrated software package for drug dosage regimen calculation and therapeutic drug monitoring. Comput. Biol. Med. 22(3), 155-163 (1992).
20. Proost JH. Adaptive control of drug dosage regimens using maximum a posteriori probability Bayesian fitting. Int. J. Clin. Pharmacol. Ther. 33(10), 531-536 (1995).
21. Trame MN, Bergstrand M, Karlsson MO, Boos J, Hempel G. Population pharmacokinetics of busulfan in children: increased evidence for body surface area and allometric body weight dosing of busulfan in children. Clin. Cancer Res. 17(21), 6867-6877 (2011).
22. McCune JS, Baker KS, Blough DK et al. Variation in prescribing patterns and therapeutic drug monitoring of intravenous busulfan in pediatric hematopoietic cell transplant recipients. J. Clin. Pharmacol. 53(3), 264-275 (2013).
23. Purcell S, Neale B, Todd-Brown K et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am. J. Hum. Genet. 81(3), 559-575 (2007).
24. Czerwinski M, Gibbs JP, Slattery JT. Busulfan conjugation by glutathione S-transferases alpha, mu, and pi. Drug Metab. Dispos. 24(9), 1015-1019 (1996).
25. Bartelink IH, Boelens JJ, Bredius RG et al. Body weight-dependent pharmacokinetics of busulfan in paediatric haematopoietic stem cell transplantation patients: towards individualized dosing. Clin. Pharmacokinet. 51(5), 331-345 (2012).
26. Bertholle-Bonnet V, Bleyzac N, Galambrun C et al. Influence of underlying disease on busulfan disposition in pediatric bone marrow transplant recipients: a nonparametric population pharmacokinetic study. Ther. Drug Monit. 29(2), 177-184 (2007).
27. Yeh RF, Pawlikowski M.A., Blough DK et al. Accurate targeting of daily intravenous busulfan with 8-hour blood sampling in hospitalized adult hematopoietic cell transplant recipients. Biol. Blood Marrow Transplant. 18(2), 265-272 (2012).
28. Ho JW, Ho PW, Liu HF et al. UCP4 is a target effector of the NF-kB c-Rel prosurvival pathway against oxidative stress. Free Radic. Biol. Med. 53(2), 383-394 (2012).